Goserelin is a synthetic peptide modeled on gonadotropin-releasing hormone (GnRH), the brain signal that starts the reproductive hormone chain. FDA first approved it as Zoladex in 1989. Its label covers prostate cancer, breast cancer, endometriosis and endometrial thinning. This guide covers its structure, label, trials and status, using sources checked on November 17, 2026.
Quick answer: Goserelin is a prescription GnRH agonist sold as Zoladex. It first raises, then suppresses, the pituitary hormones that drive testosterone and estrogen. Its label approves it for certain prostate cancers, advanced breast cancer in pre- and perimenopausal women, endometriosis and endometrial thinning. Hot flashes are among the most common label side effects.
Vitrapep does not sell goserelin; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is goserelin?
Goserelin is a short synthetic peptide. The FDA label calls it “a synthetic decapeptide analogue of GnRH” (Zoladex label, 2026). Decapeptide means a chain of ten amino acids.
The label gives the sequence as pyro-Glu-His-Trp-Ser-Tyr-D-Ser(But)-Leu-Arg-Pro-Azgly-NH2. Two positions differ from natural GnRH. Position 6 holds a D-serine carrying a tert-butyl group. Position 10 holds aza-glycine amide. PubChem lists the formula C59H84N18O14 and a molecular weight of 1269.4 g/mol (PubChem CID 5311128).
Drugs@FDA lists the original Zoladex approval on December 29, 1989 (Drugs@FDA, NDA 019726). A second Zoladex product followed on January 11, 1996 (Drugs@FDA, NDA 020578). TerSera Therapeutics now holds both. FDA first approved goserelin in 1989 as Zoladex. For the natural hormone it mimics, see our gonadorelin guide and our overview of peptide hormones.
Goserelin: key facts
| Fact | Detail |
|---|---|
| Structure | Linear peptide of ten amino acids; GnRH analogue with D-Ser(tBu) at position 6 and aza-glycine amide at position 10 |
| Class | GnRH agonist |
| Molecular formula | C59H84N18O14 (PubChem, free base) |
| Molecular weight | 1269.4 g/mol (PubChem) |
| First FDA approval | December 29, 1989 (Zoladex) |
| Brand names | Zoladex (two FDA-approved products) |
How does goserelin work?
Goserelin acts on GnRH receptors in the pituitary gland. The label describes two phases. At first, goserelin “causes an initial increase in serum luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels,” and testosterone rises in men. With continued exposure, it “leads to sustained suppression of pituitary gonadotropins.” Testosterone then falls into the range seen in surgically castrated men (Zoladex label, 2026).
The label notes the same early rise in estrogen in women with breast cancer. This early rise is the basis of its tumor flare warning. In a breast cancer trial, goserelin then lowered estradiol to postmenopausal levels (Taylor et al., 1998). The label also cites animal and laboratory studies in which goserelin shrank or slowed hormone-sensitive rat mammary and prostate tumors. Those are animal data, not human results.
What is goserelin approved for?
Section 1 of the current Zoladex label, revised March 2026, lists five indications (Zoladex label, 2026):
- use with flutamide for “the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate”;
- “palliative treatment of advanced carcinoma of the prostate”;
- “management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy”;
- use “as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding”; and
- “palliative treatment of advanced breast cancer in pre- and perimenopausal women.”
The second Zoladex product, first approved in 1996, lists only the two prostate cancer indications in its section 1 (Zoladex label, 2026).
What did the key trials of goserelin show?
EORTC 22863 (prostate cancer). This European phase 3 trial enrolled 415 men with locally advanced prostate cancer from 1987 to 1995 (NCT00849082). Men received radiotherapy alone or radiotherapy plus goserelin started at the same time. The combined arm also had a short course of cyproterone acetate. Five-year overall survival was 79% with the combination and 62% with radiotherapy alone (P=0.001). Among survivors, 85% and 48% were free of disease at five years (Bolla et al., 1997).
At ten years, overall survival was 58.1% with the combination and 39.8% with radiotherapy alone (hazard ratio 0.60, 95% CI 0.45 to 0.80). Cardiovascular deaths did not differ significantly between arms (Bolla et al., 2010). These are human data.
Label trial for Stage B2-C prostate cancer. The label describes a trial of 466 men comparing hormonal therapy plus radiation with radiation alone. Local failure at four years was 16% versus 33% (P<0.001). Median disease-free survival was 4.4 versus 2.6 years (Zoladex label, 2026).
Intergroup trial (breast cancer). This US trial randomized 136 eligible premenopausal women with receptor-positive metastatic breast cancer. They received goserelin or surgical removal of the ovaries. The authors reported that the two approaches “resulted in similar” failure-free and overall survival. The hazard ratio for death was 0.80 (95% CI 0.53 to 1.20). Hot flashes occurred in 75% versus 46% (Taylor et al., 1998).
What side effects does the goserelin label list?
There is no boxed warning. The label reports side effects by use (Zoladex label, 2026):
- Men with prostate cancer: reactions in more than 10% of men are “hot flashes, sexual dysfunction, decreased erections and lower urinary tract symptoms.” In a trial against orchiectomy, hot flashes occurred in 62% versus 53%.
- Women with breast cancer: in a phase 2 program of 333 patients, hot flashes occurred in 75.9% and decreased libido in 47.7%.
- Women with endometriosis: in a comparison with danazol, hot flushes occurred in 96%, vaginitis and headache in 75% each, and decreased libido in 61%.
The label’s warnings cover tumor flare, high blood sugar and diabetes, cardiovascular diseases, high calcium, hypersensitivity and severe skin reactions. They also cover QT interval prolongation, Injection Site Injury, clinical depression and the need to exclude pregnancy before use for benign gynecological conditions.
What is goserelin’s regulatory status, and is it used in research?
Drugs@FDA lists Zoladex with prescription marketing status. Its label carries warnings on diabetes and cardiovascular disease.
In sport, the World Anti-Doping Agency’s 2026 Prohibited List names goserelin under section S2.2.1, “Testosterone-stimulating peptides in males” (WADA, 2026). That entry lists GnRH “and its agonist analogues,” with goserelin as an example. Section S2 substances are prohibited at all times. Athletes should check with their anti-doping organization. Our guide to peptides on the 2026 WADA list covers the sections.
In laboratories, goserelin has a documented role in animal tumor models, as the label’s rat mammary and prostate tumor data show. For research labels in general, see what research use only means.
Frequently asked questions about goserelin
Is goserelin a GnRH agonist or antagonist?
An agonist. It first stimulates the pituitary, then suppresses it. Antagonists such as degarelix block the receptor instead. Other agonists include leuprolide and triptorelin.
Why can goserelin cause a tumor flare?
The label says goserelin, like other GnRH agonists, causes transient increases in testosterone in men and estrogen in women at first. That early rise can briefly worsen hormone-driven symptoms.
Is goserelin approved for women?
Yes. The original Zoladex label covers endometriosis, endometrial thinning and advanced breast cancer in pre- and perimenopausal women. The second Zoladex product lists prostate cancer indications only.
Is goserelin banned in sport?
WADA’s 2026 list names it under S2.2.1, testosterone-stimulating peptides in males, prohibited at all times.
What to know now
- What it is: a ten-amino-acid GnRH agonist, first approved as Zoladex on December 29, 1989.
- Approved uses: certain prostate cancers, advanced breast cancer in pre- and perimenopausal women, endometriosis and endometrial thinning.
- Key trial: EORTC 22863 showed better survival with radiotherapy plus goserelin than radiotherapy alone.
- Side effects: hot flashes and sexual effects lead the label lists; no boxed warning.
- Sport: named on WADA’s 2026 list for males, prohibited at all times.
What we’re watching
Further Zoladex label revisions after March 2026. Research comparing the heart safety of GnRH agonists and antagonists, still unresolved after the PRONOUNCE trial covered in our degarelix guide. And WADA’s 2027 Prohibited List, due to take effect on January 1, 2027.